Michael Roberts, Adaptin Bio CEO
September 3, 2024 07:00 AM EDT
Startups
R&D

Ex­clu­sive: Duke spin­out launch­es in hopes of pre­vail­ing with brain can­cer bis­pe­cif­ic where Am­gen, Roche did not

Lei Lei Wu

News Reporter

Adaptin Bio is launch­ing with plans to bring a bis­pe­cif­ic T cell en­gager for glioblas­toma, a dead­ly form of brain can­cer, in­to the clin­ic. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

Ar­bor Biotech­nolo­gies cuts ear­ly-stage dis­cov­ery work, lays off staff

Post-Hoc: Big promis­es built Mod­er­na. They might al­so be its un­do­ing

Sofinno­va’s Jim Healy on ‘more ra­tio­nal mar­ket’ as four biotech star­tups near their IPOs

Bris­tol My­ers touts LAG-3 strat­e­gy in lung can­cer as it preps for show­down with Mer­ck’s Keytru­da

A service from the Financial Times